Pharmacogenomics Clinical Specialist Mayo Clinic Phoenix , Arizona, United States
Adrijana Kekic, PharmD: No financial relationships to disclose
Treatment of psychiatric disorders such as depression and anxiety often follows a trial-and-error process. Increasing evidence has shown that pharmacogenomics (PGx) has the potential to improve drug selection by personalizing treatment based on a patient’s genetic profile. Attend this session to learn which drug classes have the most evidence related to the impact of PGx and practical considerations for using PGx in psychiatric practice.
Identify current clinical practice guidelines for drug selection and dose adjustment based on patient’s pharmacogenomics results.
Describe the role of a pharmacist in pharmacogenomics testing and guided pharmacotherapy to treat mental health conditions.
Discuss barriers to the implementation of pharmacogenomics into clinical pharmacy practice.